Glp-1 Obesity Drugs: Cigna drops coverage of GLP-1 obesity drugs for its own employees: What’s the future of weight-loss treatment
The battle over America’s booming weight-loss drug market has a significant update, with a move that’s likely to cause a shift across the healthcare and corporate benefits landscape: Cigna, one of America’s biggest insurers, is dropping coverage for GLP-1 obesity drugs, even for its own staff. This includes favorites like Wegovy and Zepbound, and it’s…